Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 1/2012

01-01-2012 | Original Paper

NS398 induces apoptosis in non-small cell lung cancer cells

Authors: Rong Qiu, Jian Chen, Jun Sima, Xiangdi Shen, Dandan Liu, Jian Shen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2012

Login to get access

Abstract

Purpose

Non-steroidal anti-inflammatory drugs (NSAIDs) can induce the apoptosis of many tumor cells and inhibit their growth. NS398 is an NSAID that inhibits COX-2 expression and induces tumor apoptosis via other pathways. The current study aims to observe the effects of NS398 on A549 cell apoptosis and investigate the apoptosis mechanism.

Methods

The A549 cells were treated with different NS398 concentrations. The growth inhibition of A549 cell was analyzed via a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and morphologic alterations were observed to detect apoptosis. The expression of survivin and caspase-3 mRNA was quantified via reverse transcriptase polymerase chain reaction, and the expression of caspase-3 and p-AKT protein was detected via western blot analysis.

Results

The MTT results show that NS398 inhibits A549 cell growth. The inhibition rate of NS398 (400 μmol/L) on A549 cells is up to 66.95% after 48 h of treatment. Simultaneously, the morphology experiment revealed significant apoptotic characteristics in A549 cells, such as green nuclear plasmid and different degrees of nuclear fragmentation. The expression of survivin mRNA was significantly reduced (P < 0.05, P < 0.01, and P < 0.001) and that of caspase-3 mRNA was significantly increased (P < 0.05 and P < 0.001) in the group treated with NS398 for 24 h in a dose-dependent manner. On the other hand, survivin and p-AKT were expressed at low levels (P < 0.01 and P < 0.001) and caspase-3 was increased significantly (P < 0.05 and P < 0.001) in the group treated with NS398 for 48 h in a dose-dependent manner.

Conclusion

The current study proves that NS398 induces apoptosis in A549 cells, thereby inhibiting tumor growth. This function of NS398 may be related to the inhibition of AKT phosphorylation and survivin protein downregulation.
Literature
go back to reference Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133–1141PubMedCrossRef Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crino L (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133–1141PubMedCrossRef
go back to reference Dalwadi H, Krysan K, Heuze-Vourc’h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S (2005) Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11:7674–7682PubMedCrossRef Dalwadi H, Krysan K, Heuze-Vourc’h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S (2005) Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11:7674–7682PubMedCrossRef
go back to reference Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR (2003) Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278:50402–50411PubMedCrossRef Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR (2003) Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278:50402–50411PubMedCrossRef
go back to reference Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S (1994) NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47:55–59PubMedCrossRef Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S (1994) NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47:55–59PubMedCrossRef
go back to reference Guo RH, Jin SD, Cai J, Huang ZH, Shu YQ (2008) Insulin/PI3K signalling pathway regulates the expression of survivin in liver cancer HepG2 cells. Zhonghua Zhong Liu Za Zhi 30:745–748PubMed Guo RH, Jin SD, Cai J, Huang ZH, Shu YQ (2008) Insulin/PI3K signalling pathway regulates the expression of survivin in liver cancer HepG2 cells. Zhonghua Zhong Liu Za Zhi 30:745–748PubMed
go back to reference Guzinska-Ustymowicz K, Kemona A (2005) Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol 11:1193–1195PubMed Guzinska-Ustymowicz K, Kemona A (2005) Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol 11:1193–1195PubMed
go back to reference Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38:756–768PubMedCrossRef Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38:756–768PubMedCrossRef
go back to reference Miao LY, Wang J, Wu Q, Sun ZT, Wu YM, Wu YJ (2007) Expression of activated AKT, survivin and Bcl-2 in human non-small cell lung cancer. Tianjin Med J 35:241–243 Miao LY, Wang J, Wu Q, Sun ZT, Wu YM, Wu YJ (2007) Expression of activated AKT, survivin and Bcl-2 in human non-small cell lung cancer. Tianjin Med J 35:241–243
go back to reference Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H (2003) Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9:1741–1749PubMed Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H (2003) Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9:1741–1749PubMed
go back to reference Niu ZY, Cheng ZY, Liu YJ, Suo XH, Zhang XJ, Pan L (2010) Effect of integrin-mediated signal transduction pathways on apoptosis of K562 cells. Cancer Res Prev Treat 37:373–377 Niu ZY, Cheng ZY, Liu YJ, Suo XH, Zhang XJ, Pan L (2010) Effect of integrin-mediated signal transduction pathways on apoptosis of K562 cells. Cancer Res Prev Treat 37:373–377
go back to reference Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281:25903–25914PubMedCrossRef Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281:25903–25914PubMedCrossRef
go back to reference Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, van Kranen HJ, Kampman E (2006) Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics 16:43–50PubMedCrossRef Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, van Kranen HJ, Kampman E (2006) Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics 16:43–50PubMedCrossRef
go back to reference Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11:3974–3986PubMedCrossRef Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11:3974–3986PubMedCrossRef
go back to reference Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M, Shiraki K (2000) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19:1346–1353PubMedCrossRef Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M, Shiraki K (2000) Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19:1346–1353PubMedCrossRef
go back to reference Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS, Munkarah A (2010) Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126:382–394PubMedCrossRef Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS, Munkarah A (2010) Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126:382–394PubMedCrossRef
go back to reference Viniegra JG, Martinez N, Modirassari P, Losa JH, Parada CC, Lobo VJ, Luquero CI, Alvarez-Vallina L, Ramon YCS, Rojas JM, Sanchez-Prieto R (2005) Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 280:4029–4036PubMedCrossRef Viniegra JG, Martinez N, Modirassari P, Losa JH, Parada CC, Lobo VJ, Luquero CI, Alvarez-Vallina L, Ramon YCS, Rojas JM, Sanchez-Prieto R (2005) Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 280:4029–4036PubMedCrossRef
go back to reference Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, Brattain MG (2008) Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 68:3152–3160PubMedCrossRef Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, Liu XQ, Hauser J, Brattain MG (2008) Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 68:3152–3160PubMedCrossRef
go back to reference Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T (2006) COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18:41–47PubMed Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T (2006) COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18:41–47PubMed
Metadata
Title
NS398 induces apoptosis in non-small cell lung cancer cells
Authors
Rong Qiu
Jian Chen
Jun Sima
Xiangdi Shen
Dandan Liu
Jian Shen
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-1080-3

Other articles of this Issue 1/2012

Journal of Cancer Research and Clinical Oncology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.